Biogen Board Appoints Two New Independent Directors
Biogen Inc. (Nasdaq: BIIB) has announced the appointment of two new independent directors to its Board. Dr. Lloyd Minor, Dean of Stanford University School of Medicine, will join on October 1, 2024, and Prof Sir Menelas Pangalos, former Executive VP of Biopharmaceuticals R&D at AstraZeneca, will join on January 1, 2025.
These appointments bring significant scientific expertise and experience in medicine research and development to Biogen's Board. Dr. Minor has played a key role in Stanford Medicine's strategy and leadership, while Prof Sir Pangalos has a strong track record in biopharmaceutical R&D transformation.
The Board expects these new directors to contribute fresh perspectives and deep scientific knowledge to bolster Biogen's portfolio and drive long-term, sustainable growth.
Biogen Inc. (Nasdaq: BIIB) ha annunciato la nomina di due nuovi membri indipendenti nel suo Consiglio di Amministrazione. Dr. Lloyd Minor, Decano della Stanford University School of Medicine, entrerà in carica il 1 ottobre 2024, e Prof Sir Menelas Pangalos, ex Vicepresidente Esecutivo della R&S Biopharmaceuticals di AstraZeneca, si unirà il 1 gennaio 2025.
Queste nomine apportano una significativa expertise scientifica ed esperienza nella ricerca e nello sviluppo medico al Consiglio di Biogen. Il Dr. Minor ha svolto un ruolo chiave nella strategia e nella leadership della Stanford Medicine, mentre il Prof Sir Pangalos ha un solido curriculum nella trasformazione della R&S biopharma.
Il Consiglio si aspetta che questi nuovi direttori contribuiscano con prospettive fresche e una profonda conoscenza scientifica per rafforzare il portafoglio di Biogen e promuovere una crescita sostenibile a lungo termine.
Biogen Inc. (Nasdaq: BIIB) ha anunciado el nombramiento de dos nuevos directores independientes para su Junta. Dr. Lloyd Minor, Decano de la Escuela de Medicina de la Universidad de Stanford, se unirá el 1 de octubre de 2024, y Prof. Sir Menelas Pangalos, ex Vicepresidente Ejecutivo de I+D de Biofármacos en AstraZeneca, se unirá el 1 de enero de 2025.
Estos nombramientos aportan una experiencia científica significativa y un amplio conocimiento en investigación y desarrollo médico a la Junta de Biogen. El Dr. Minor ha desempeñado un papel clave en la estrategia y liderazgo de Stanford Medicine, mientras que el Prof. Sir Pangalos tiene un sólido historial en la transformación de I+D biofarmacéutica.
Se espera que estos nuevos directores aporten nuevas perspectivas y un profundo conocimiento científico para fortalecer el portafolio de Biogen y fomentar un crecimiento sostenible a largo plazo.
Biogen Inc. (Nasdaq: BIIB)는 이사회에 두 명의 새로운 독립 이사를 임명했다고 발표했습니다. Dr. Lloyd Minor는 스탠포드 대학교 의과대학의 학장이며, 2024년 10월 1일부터 합류할 예정이며, Prof Sir Menelas Pangalos는 아스트라제네카의 생물제약 연구개발 부문 전 부사장이며 2025년 1월 1일부터 합류합니다.
이번 임명은 Biogen의 이사회에 의학 연구 및 개발 분야의 중요한 과학적 전문성과 경험을 제공합니다. Dr. Minor는 스탠포드 의학의 전략 및 리더십에서 중요한 역할을 해왔고, Prof Sir Pangalos는 생물제약 연구개발의 변혁에 대한 강력한 실적을 보유하고 있습니다.
이사회는 이 두 새로운 이사들이 Biogen의 포트폴리오를 강화하고 장기적인 지속 가능한 성장을 추진하기 위해 신선한 관점과 깊은 과학적 지식을 기여할 것으로 기대하고 있습니다.
Biogen Inc. (Nasdaq: BIIB) a annoncé la nomination de deux nouveaux administrateurs indépendants au sein de son Conseil. Dr. Lloyd Minor, Doyen de l'École de médecine de l'Université de Stanford, rejoindra le 1er octobre 2024, et Prof Sir Menelas Pangalos, ancien Vice-Président Exécutif de la R&D des biopharmaceutiques chez AstraZeneca, rejoindra le 1er janvier 2025.
Ces nominations apportent une expertise scientifique importante et une expérience dans la recherche et le développement médical au Conseil de Biogen. Le Dr. Minor a joué un rôle clé dans la stratégie et la direction de la Stanford Medicine, tandis que le Prof. Sir Pangalos a un solide parcours dans la transformation de la R&D biopharmaceutique.
Le Conseil s'attend à ce que ces nouveaux administrateurs apportent de nouvelles perspectives et une connaissance scientifique approfondie pour renforcer le portefeuille de Biogen et favoriser une croissance durable à long terme.
Biogen Inc. (Nasdaq: BIIB) hat die Ernennung von zwei neuen unabhängigen Direktoren zu seinem Vorstand bekanntgegeben. Dr. Lloyd Minor, Dekan der Stanford University School of Medicine, wird am 1. Oktober 2024 dazustoßen, und Prof. Sir Menelas Pangalos, ehemaliger Executive VP für Biopharmazeutische Forschung und Entwicklung bei AstraZeneca, wird am 1. Januar 2025 eintreten.
Diese Ernennungen bringen bedeutende wissenschaftliche Expertise und Erfahrung in der medizinischen Forschung und Entwicklung in den Vorstand von Biogen ein. Dr. Minor hat eine Schlüsselrolle in der Strategie und Führung der Stanford Medicine gespielt, während Prof. Sir Pangalos eine starke Erfolgsbilanz in der Transformation der biopharmazeutischen Forschung und Entwicklung vorweisen kann.
Der Vorstand erwartet, dass diese neuen Direktoren frische Perspektiven und tiefgehendes wissenschaftliches Wissen einbringen, um Biogens Portfolio zu stärken und ein langfristiges, nachhaltiges Wachstum voranzutreiben.
- Addition of two highly experienced directors with strong backgrounds in medical research and biopharmaceutical R&D
- Potential for fresh perspectives and deep scientific knowledge to bolster Biogen's portfolio
- Expectation of contributions towards long-term, sustainable growth and positive patient outcomes
- None.
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024.
“We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D in the life sciences and biopharmaceutical industries,” said Caroline Dorsa, Chair of the Biogen Board of Directors. “Lloyd and Mene will bring fresh perspectives and deep scientific knowledge to our efforts to bolster the company’s portfolio and achieve long-term, sustainable growth and positive outcomes for patients.”
As Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, Dr. Minor has played an integral role in establishing strategy across the enterprise of Stanford Medicine, leading all health and medicine matters in research, clinical care and education at Stanford University, and driving the transformation of the future of life sciences at the university. Prior to his current role, he was Provost and Senior Vice President for Academic Affairs at Johns Hopkins University, where he also previously served as the Andelot Professor and Chair of the Department of Otolaryngology at the School of Medicine and as otolaryngologist-in-chief of the Johns Hopkins Hospital. In 2012, Dr. Minor was elected to the National Academy of Medicine.
Dr. Minor has a Sc.B. from Brown University and received his M.D. from the Warren Alpert Medical School of Brown University. He is the chair of the board of directors of the Alice L. Walton School of Medicine, a new medical school being established in Bentonville, Arkansas. His other board and advisory activities include serving on the board of directors of Atrio Health Plans and Caris Life Sciences as well as advisory roles for Goldman Sachs and General Atlantic.
Prof Sir Pangalos was previously Executive Vice President of Biopharmaceuticals R&D at AstraZeneca. In this role, Prof Sir Pangalos was responsible for biopharmaceutical R&D from discovery through late-stage development, covering areas including cardiovascular, autoimmune and neurology. He joined AstraZeneca in 2010 as Executive Vice President of Early R&D and led the transformation of the company’s R&D productivity, as well as overseeing the creation of AstraZeneca’s new Global R&D Center in Cambridge, UK. He previously held senior R&D roles at Pfizer, Wyeth and GSK.
Prof Sir Pangalos has a B.S. in Biochemistry and Molecular Biology from Imperial College London and received his Ph.D. in Neuropharmacology from University College London. He is an elected Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He serves on the boards of The Francis Crick Institute, The Judge Business School, Cambridge University and Absci Corporation.
“Lloyd and Mene bring research and development knowledge and industry experience to our Board that will be greatly additive as we continue to advance Biogen into its next chapter of sustainable growth,” said Christopher A. Viehbacher, Biogen President and Chief Executive Officer. “With their collective research expertise and success driving R&D transformation, they will make immediate and substantive contributions to Biogen as we continue to expand our portfolio. I look forward to working with them alongside the rest of our Board at this important moment for Biogen.”
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; and our future financial and operating results. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT: Jack Cox + 1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT: Chuck Triano +1 781 464 2442 IR@biogen.com | |
FAQ
Who are the new independent directors appointed to Biogen's Board?
What expertise do the new Biogen Board members bring?
When will the new directors join Biogen's Board?
How does Biogen expect these appointments to impact the company?
